CellCarta Acquires Commercial Rights to Immuno‑MRM Assays from Precision Assays

CellCarta Acquires Biogazelle

December 14, 2021

Biotechnology

CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.

Atlas Antibodies Acquires HistoCyte Laboratories Ltd

February 1, 2021

Medical Devices

Atlas Antibodies AB has signed an agreement to acquire UK-based HistoCyte Laboratories Ltd, a maker of cell-line control materials for immunohistochemical assays. The deal combines Atlas's proteome-wide antibody reagent portfolio with HistoCyte's novel control materials to expand diagnostic and research offerings; closing was expected in early March 2021.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

CellCarta Acquires Reveal Biosciences

May 11, 2021

Healthcare Services

CellCarta has acquired Reveal Biosciences, a San Diego–based computational pathology company specializing in AI-driven quantitative pathology and digital image analysis. The acquisition adds Reveal's imageDx platform and AI-based pathology capabilities to CellCarta's histological biomarker and precision medicine services, broadening its AI-enabled multi-omic analysis offerings for biopharmaceutical research and clinical trials.

BioIVT Acquires PrecisionMed

July 18, 2023

Healthcare Services

BioIVT, a global biospecimen solutions provider, has acquired PrecisionMed, LLC, a Carlsbad-based supplier of high-quality human biospecimens and owner of a large longitudinal cerebrospinal fluid (CSF) repository. The acquisition expands BioIVT's supply network, inventory and capacity for CSF and liquid biopsy products while PrecisionMed will continue to operate from its existing headquarters and collection sites.

Merck Acquires OncoImmune

November 23, 2020

Biotechnology

Merck will acquire all outstanding shares of clinical-stage biopharmaceutical OncoImmune for $425 million upfront in cash, with additional sales-based and regulatory milestone payments possible. The deal centers on accelerating development of OncoImmune’s CD24Fc for severe and critical COVID-19; non-CD24Fc assets will be spun out into a new company in which Merck will invest $50 million for a minority stake.